- Home
- UCAR vs KAPA Comparison
UCAR vs KAPA Comparison
Compare UCAR & KAPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCAR
- KAPA
- Stock Information
- Founded
- UCAR 2013
- KAPA 2013
- Country
- UCAR China
- KAPA United States
- Employees
- UCAR N/A
- KAPA N/A
- Industry
- UCAR Retail-Auto Dealers and Gas Stations
- KAPA
- Sector
- UCAR Consumer Discretionary
- KAPA
- Exchange
- UCAR Nasdaq
- KAPA NYSE
- Market Cap
- UCAR 23.3M
- KAPA 19.9M
- IPO Year
- UCAR 2023
- KAPA 2024
- Fundamental
- Price
- UCAR $7.78
- KAPA $1.63
- Analyst Decision
- UCAR
- KAPA Strong Buy
- Analyst Count
- UCAR 0
- KAPA 1
- Target Price
- UCAR N/A
- KAPA $9.00
- AVG Volume (30 Days)
- UCAR 43.6K
- KAPA 6.1M
- Earning Date
- UCAR 10-08-2024
- KAPA 02-23-2025
- Dividend Yield
- UCAR N/A
- KAPA N/A
- EPS Growth
- UCAR N/A
- KAPA N/A
- EPS
- UCAR N/A
- KAPA N/A
- Revenue
- UCAR $4,273,899.00
- KAPA N/A
- Revenue This Year
- UCAR N/A
- KAPA N/A
- Revenue Next Year
- UCAR N/A
- KAPA N/A
- P/E Ratio
- UCAR N/A
- KAPA N/A
- Revenue Growth
- UCAR 473.55
- KAPA N/A
- 52 Week Low
- UCAR $4.21
- KAPA $0.85
- 52 Week High
- UCAR $12.80
- KAPA $4.00
- Technical
- Relative Strength Index (RSI)
- UCAR 53.24
- KAPA N/A
- Support Level
- UCAR $6.50
- KAPA N/A
- Resistance Level
- UCAR $9.43
- KAPA N/A
- Average True Range (ATR)
- UCAR 0.86
- KAPA 0.00
- MACD
- UCAR 0.14
- KAPA 0.00
- Stochastic Oscillator
- UCAR 46.19
- KAPA 0.00
About UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufactory and sales; battery swapping services and sourcing services. The company as a broker engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About KAPA KAIROS PHARMA LTD
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.